In this episode, we explore the evolving role of surrogate endpoints in the management of IgA nephropathy (IgAN), with a particular focus on the significance of estimated glomerular filtration rate (eGFR). Of the completed Phase 3 trials in IgAN, one used time-weighted average eGFR, an area under the curve-based measure that reflects the average change in eGFR from baseline over a specified period, in this case, over the full 2-year study period. The other trial used total eGFR slope to describe the overall rate of change over 2 years. But what do these endpoints mean outside the setting of a clinical trial? Expert insights shed light on how proteinuria and eGFR trends can inform prognosis and guide treatment decisions in clinical practice over the long term. Listeners will gain a deeper understanding of how to interpret eGFR changes over time and apply this knowledge to optimize patient care. Designed for nephrology professionals, this episode offers practical, evidence-based perspectives on integrating these surrogate endpoints into the care of patients with IgAN. Supported by Calliditas Therapeutics Upon completion of the podcast, please take a moment to complete a brief survey: https://kidneyforms.tfaforms.net/4728109